Engaged in share buyback. Targets 60,600 ordinary shares, total amount 192,845,500 yen, period 2026\/6\/1\u20132026\/6\/30, method is market purchase (Tokyo Stock Exchange).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Molnex Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4534-20260701-01.pdf","jir_short_summary":"Engaged in share buyback. Targets 60,600 ordinary shares, total amount 192,845,500 yen, period 2026\/6\/1\u20132026\/6\/30, method is market purchase (Tokyo Stock Exchange).","jir_summary":"### Key points of the acquisition\nToday, we disclosed the status of our share buyback. The target shares are ordinary shares, total number 60,600 shares, total acquisition value 192,845,500 yen. Acquisition period is from June 1, 2026 to June 30, 2026 on an execution basis, with the transaction method being market purchases. The maximum acquisition framework and period were disclosed based on the board of directors' meeting resolution held on March 30, 2026; cumulatively, as of June 30, 2026, total acquired shares are 95,900 shares, and total amount is 317,160,500 yen.\n\n### Market impact and future outlook\nThe share buyback is conducted as part of shareholder remittance measures, potentially aiming to counter dilution and support the share price. This acquisition is conducted via market purchases, and the cumulative status will continue to be disclosed. Future acquisition progress and any additional board resolutions are points to watch.","jir_financial_highlights":"Total number of acquired shares: 60,600 shares (Unknown)\nTotal acquisition value: 192,845,500 yen (Unknown)\nAcquisition period: June 1, 2026 to June 30, 2026 (Unknown)","jir_category":"","jir_hashtags":"#MolnexPharmaceutical, #ShareBuyback, #IR","jir_key_figures":"60,600 shares: Total number of acquired shares\n192,845,500 yen: Total acquisition value\nJune 1, 2026 \u2013 June 30, 2026: Acquisition period\nCumulative 95,900 shares: Cumulative total acquired around the above period\nCumulative 317,160,500 yen: Cumulative total acquisition value around the above period","jir_meta_title":"[Molnex Pharmaceutical] Disclosure of Share Buyback Status | June 2026 Results","jir_meta_description":"Molnex Pharmaceutical announces share buyback. 60,600 shares acquired, total 192,845,500 yen, period 2026\/6\/1\u20132026\/6\/30. Cumulative 95,900 shares and 317,160,500 yen. Conducted via market purchases.","jir_og_title":"[Molnex Pharmaceutical] Disclosure of Share Buyback Status | June 2026 Results","jir_og_description":"Molnex Pharmaceutical announces share buyback. 60,600 shares acquired, total 192,845,500 yen, period 2026\/6\/1-2026\/6\/30. Cumulative 95,900 shares and 317,160,500 yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-74007","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n